FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3140246456> ?p ?o ?g. }

• W3140246456 endingPage "67" @default.
• W3140246456 startingPage "56" @default.
• W3140246456 abstract "<h3>Purpose</h3> Accelerated partial breast irradiation (APBI) represents a validated technique for low-risk breast cancer. Recently, ultra-APBI (uAPBI) using fewer than 5 fractions was described in the literature. We compared clinical outcomes and late toxicity after APBI or uAPBI in older patients. <h3>Methods and Materials</h3> Two cohorts of older patients (aged ≥70 years) with low-risk breast cancer treated with APBI (interstitial brachytherapy) were analyzed retrospectively. A total dose of 34 Gy in10 fractions (APBI) or 16 Gy in 1 fraction (uAPBI) was delivered from 2004 to 2012 and from 2013 to 2018, respectively. Oncologic outcome analyzed the cumulative incidence of local relapse, regional relapse, and distant metastases with disease-free survival, cause-specific survival, and overall survival. Late toxicity and cosmetic results were investigated. <h3>Results</h3> One hundred fifty-seven patients (APBI, n = 109 patients; uAPBI, n = 48 patients) underwent APBI according to the same selection criteria. Apart from the median follow-up (97 vs 72 months for APBI and uAPBI; <i>P</i> < .002), no significant difference was noted between the 2 groups. Regarding 6-year oncologic outcome, no significant difference was observed between APBI and uAPBI for local recurrence (1.3% vs 0%; <i>P</i> = .4), regional recurrence (2.5% vs 2.3%; <i>P</i> = .9), distant metastases (4.3% vs. 2.4%; <i>P</i> = .6), disease-free survival (85.2% vs. 82.2%; <i>P</i> = .8), cause-specific survival (96.7% vs. 96.2%; <i>P</i> = .9), and overall survival (86.7% vs. 82.2%; <i>P</i> = .7). Regarding late toxicity, no significant difference was observed between APBI and uAPBI (total complication number, 45 vs 33%; <i>P</i> = .173) with only grade 1 (88.4% vs. 95%) and grade 2 (11.6% vs. 5%) late toxicities (<i>P</i> = .677). Similarly, no significant difference was observed for excellent/good cosmetic results between the 2 cohorts (<i>P</i> = .98). <h3>Conclusions</h3> We report the first study comparing APBI versus uAPBI in a cohort of older patients with low-risk breast cancer. No significant difference was found between the 2 treatment groups regarding oncologic outcome, late toxicity, and cosmetic result. uAPBI based on a single fraction of brachytherapy represents an attractive option for therapeutic de-escalation in older patients with breast cancer." @default.
• W3140246456 created "2021-04-13" @default.
• W3140246456 creator A5005749193 @default.
• W3140246456 creator A5041049746 @default.
• W3140246456 creator A5051063466 @default.
• W3140246456 creator A5066227680 @default.
• W3140246456 creator A5070991360 @default.
• W3140246456 creator A5082015086 @default.
• W3140246456 creator A5082215736 @default.
• W3140246456 creator A5086966250 @default.
• W3140246456 date "2021-09-01" @default.
• W3140246456 modified "2023-10-16" @default.
• W3140246456 title "APBI Versus Ultra-APBI in the Elderly With Low-Risk Breast Cancer: A Comparative Analysis of Oncological Outcome and Late Toxicity" @default.
• W3140246456 cites W1968626722 @default.
• W3140246456 cites W1980777855 @default.
• W3140246456 cites W1982853521 @default.
• W3140246456 cites W1988452219 @default.
• W3140246456 cites W2017188211 @default.
• W3140246456 cites W2023494838 @default.
• W3140246456 cites W2027344979 @default.
• W3140246456 cites W2043468165 @default.
• W3140246456 cites W2052577752 @default.
• W3140246456 cites W2083825568 @default.
• W3140246456 cites W2098560759 @default.
• W3140246456 cites W2100787775 @default.
• W3140246456 cites W2106132194 @default.
• W3140246456 cites W2128585633 @default.
• W3140246456 cites W2146522000 @default.
• W3140246456 cites W2149455283 @default.
• W3140246456 cites W2151393118 @default.
• W3140246456 cites W2169838582 @default.
• W3140246456 cites W2178502550 @default.
• W3140246456 cites W2346251131 @default.
• W3140246456 cites W2577994305 @default.
• W3140246456 cites W2592150536 @default.
• W3140246456 cites W2729131999 @default.
• W3140246456 cites W2743595252 @default.
• W3140246456 cites W2772069710 @default.
• W3140246456 cites W2790448615 @default.
• W3140246456 cites W2790676761 @default.
• W3140246456 cites W2802518623 @default.
• W3140246456 cites W2905893840 @default.
• W3140246456 cites W2907779076 @default.
• W3140246456 cites W2970373007 @default.
• W3140246456 cites W2991472044 @default.
• W3140246456 cites W2992619229 @default.
• W3140246456 cites W2993667428 @default.
• W3140246456 cites W2996137958 @default.
• W3140246456 cites W3022548009 @default.
• W3140246456 cites W3099703940 @default.
• W3140246456 cites W3132885365 @default.
• W3140246456 cites W4234066875 @default.
• W3140246456 doi "https://doi.org/10.1016/j.ijrobp.2021.03.052" @default.
• W3140246456 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33831490" @default.
• W3140246456 hasPublicationYear "2021" @default.
• W3140246456 type Work @default.
• W3140246456 sameAs 3140246456 @default.
• W3140246456 citedByCount "12" @default.
• W3140246456 countsByYear W31402464562021 @default.
• W3140246456 countsByYear W31402464562022 @default.
• W3140246456 countsByYear W31402464562023 @default.
• W3140246456 crossrefType "journal-article" @default.
• W3140246456 hasAuthorship W3140246456A5005749193 @default.
• W3140246456 hasAuthorship W3140246456A5041049746 @default.
• W3140246456 hasAuthorship W3140246456A5051063466 @default.
• W3140246456 hasAuthorship W3140246456A5066227680 @default.
• W3140246456 hasAuthorship W3140246456A5070991360 @default.
• W3140246456 hasAuthorship W3140246456A5082015086 @default.
• W3140246456 hasAuthorship W3140246456A5082215736 @default.
• W3140246456 hasAuthorship W3140246456A5086966250 @default.
• W3140246456 hasBestOaLocation W31402464561 @default.
• W3140246456 hasConcept C121608353 @default.
• W3140246456 hasConcept C126322002 @default.
• W3140246456 hasConcept C143998085 @default.
• W3140246456 hasConcept C29730261 @default.
• W3140246456 hasConcept C530470458 @default.
• W3140246456 hasConcept C71924100 @default.
• W3140246456 hasConceptScore W3140246456C121608353 @default.
• W3140246456 hasConceptScore W3140246456C126322002 @default.
• W3140246456 hasConceptScore W3140246456C143998085 @default.
• W3140246456 hasConceptScore W3140246456C29730261 @default.
• W3140246456 hasConceptScore W3140246456C530470458 @default.
• W3140246456 hasConceptScore W3140246456C71924100 @default.
• W3140246456 hasIssue "1" @default.
• W3140246456 hasLocation W31402464561 @default.
• W3140246456 hasOpenAccess W3140246456 @default.
• W3140246456 hasPrimaryLocation W31402464561 @default.
• W3140246456 hasRelatedWork W1722328147 @default.
• W3140246456 hasRelatedWork W1984086083 @default.
• W3140246456 hasRelatedWork W2146717458 @default.
• W3140246456 hasRelatedWork W2297614534 @default.
• W3140246456 hasRelatedWork W2557359331 @default.
• W3140246456 hasRelatedWork W2892677547 @default.
• W3140246456 hasRelatedWork W2989121736 @default.
• W3140246456 hasRelatedWork W3013730050 @default.
• W3140246456 hasRelatedWork W3030288240 @default.
• W3140246456 hasRelatedWork W2342209702 @default.
• W3140246456 hasVolume "111" @default.

• next